Abd Rahim Iman Nabilah, Mohd Kasim Noor Alicezah, Isa Mohamad Rodi, Nawawi Hapizah
Institute of Pathology, Laboratory and Forensic Medicine (I-PperForM), Universiti Teknologi MARA, Selangor, Malaysia.
Department of Pathology, Faculty of Medicine, Universiti Teknologi MARA, Selangor, Malaysia.
Malays J Med Sci. 2022 Aug;29(4):14-27. doi: 10.21315/mjms2022.29.4.3. Epub 2022 Aug 29.
Saffron is widely used in traditional medicine to treat various medical disorders, including hyperlipidaemia. This study aims to systematically review the effects of saffron extract (SE) on lipid profile in in vivo studies. A strategic literature search was done following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Scopus, PubMed (MEDLINE) and Web of Science databases and hand-searching methods were utilised to identify studies published up to January 2020 that reported the effects of SE on lipid profile in a hyperlipidaemic experimental animal model. A total of six articles met the inclusion criteria. The methods of extraction were aqueous ( = 4), ethanolic ( = 1) and hydroalcoholic ( = 1) extracts. Five doses of SE ranging from 10 mg/kg to 100 mg/kg were administered to rats and hamsters, with a duration ranging from 10 days to 8 weeks. SE at doses of 40 mg/kg/day and 80 mg/kg/day significantly decreased the levels of total cholesterol (21.4%-35.4%), low-density lipoproteins (38.7%-50.0%) and triglycerides (TGs) (29.1%-45.0%) and markedly increased the level of high-density lipoproteins (36.6%-65%) in the treated group compared to the untreated group with a minimum 3-week intervention duration ( < 0.05). This systematic review demonstrated that SE exhibits hypolipidaemic effects compared to a placebo. SE has almost the same ability to reduce cholesterol levels as the standard therapy.
藏红花在传统医学中被广泛用于治疗各种疾病,包括高脂血症。本研究旨在系统评价藏红花提取物(SE)在体内研究中对血脂谱的影响。按照系统评价和Meta分析的首选报告项目(PRISMA)指南进行了策略性文献检索。利用Scopus、PubMed(MEDLINE)和Web of Science数据库以及手工检索方法,识别截至2020年1月发表的报告SE对高脂血症实验动物模型血脂谱影响的研究。共有6篇文章符合纳入标准。提取方法有水提(=4)、醇提(=1)和水醇提(=1)。给大鼠和仓鼠施用5种剂量的SE,范围从10mg/kg至100mg/kg,持续时间从10天至8周。与未治疗组相比,在至少3周的干预持续时间下,剂量为40mg/kg/天和80mg/kg/天的SE显著降低了治疗组的总胆固醇水平(21.4%-35.4%)、低密度脂蛋白水平(38.7%-50.0%)和甘油三酯(TGs)水平(29.1%-45.0%),并显著提高了高密度脂蛋白水平(36.6%-65%)(P<0.05)。该系统评价表明,与安慰剂相比,SE具有降血脂作用。SE降低胆固醇水平的能力与标准疗法几乎相同。